Milestone Pharmaceuticals (MIST) Non-Current Debt (2023 - 2026)
Milestone Pharmaceuticals' (MIST) quarterly Non-Current Debt came in at $58.2 million in Q1 2026, up 7.19% YoY from $54.3 million in Q1 2025, and up 1.75% on a QoQ basis from $57.2 million in Q4 2025.
Milestone Pharmaceuticals (MIST) Non-Current Debt (2023 - 2026) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 4 years of Non-Current Debt data on file, last reported at $58.2 million in Q1 2026.
- Quarterly Non-Current Debt rose 7.19% year-over-year to $58.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.2 million (up 7.19% YoY) and the FY2025 annual result came in at $57.2 million, up 7.2% from the prior year.
- Non-Current Debt advanced to $58.2 million in Q1 2026, from $57.2 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $58.2 million in Q1 2026 to a low of $47.3 million in Q1 2023.
- A 4-year average of $52.6 million and a median of $52.4 million in 2024 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2024 — Non-Current Debt gained 7.02% — and 2025, when it climbed 7.2%.
- Tracing MIST's Non-Current Debt over 4 years: stood at $49.8 million in 2023, then climbed by 7.19% to $53.4 million in 2024, then rose by 7.2% to $57.2 million in 2025, then climbed by 1.75% to $58.2 million in 2026.
- The last three Non-Current Debt figures came in at $58.2 million (Q1 2026), $57.2 million (Q4 2025), and $56.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Milestone Pharmaceuticals | 43.40 Mn | -128.10 Mn | - | 59.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.21 Mn |
| Mar 31, 2026 | 58.19 Mn |
| Dec 31, 2025 | 57.19 Mn |
| Sep 30, 2025 | 56.21 Mn |
| Jun 30, 2025 | 55.24 Mn |
| Mar 31, 2025 | 54.29 Mn |
| Dec 31, 2024 | 53.35 Mn |
| Sep 30, 2024 | 52.43 Mn |
| Jun 30, 2024 | 51.53 Mn |
| Mar 31, 2024 | 50.64 Mn |
| Dec 31, 2023 | 49.77 Mn |
| Sep 30, 2023 | 48.92 Mn |
| Jun 30, 2023 | 48.07 Mn |
| Mar 31, 2023 | 47.32 Mn |